3 results
Approved WMORecruiting
In this study, we look at how safe the new medicinal product rusfertide is for the treatment of Polycythemia vera. And how well it works.
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMORecruiting
The study is divided in two phases.The primary objective of phase I of the study is to evaluate the safety and toxicity of the infusion of ex vivo expanded RNK001 NK cells, both with and without sc IL-2 following immunosuppressive conditioning…